Supportive Solid Tumor Studies

Non-therapeutic protocols address such issues as side effects or long-term effects of therapy, quality of life, making testing easier on the children, prevention of pain, and issues related to nutrition and stress. There are also tissue and blood banking protocols for laboratory researchers who are studying diseases and searching for underlying causes and cures. The research at St. Jude is designed to include all aspects related to the care of sick children and their families.

St. Jude Clinical Trials

DWSARC: Diffusion Weighted Magnetic Resonance Imaging In Pediatric Sarcomas

Diseases Treated:

Solid tumors

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant is under the care of a St. Jude physician with a known or suspected, newly diagnosed bone or soft tissue sarcoma who will be treated on or as per disease specific protocols and has not begun therapy OR participant has started therapy and the needed research imaging can be performed within 2-5 days of starting treatment. 
  • Participant has undergone or is scheduled for PET-CT, Bone Scan, or PET-CT and Bone Scan within two (2) weeks of the whole body and primary tumor DWI-MRI. 
  • Participant meets institutional MRI safety screening requirements. 
  • Participant has not undergone primary tumor resection prior to arrival to St. Jude
View Trial

IPACTR: International Pediatric Adrenocortical Tumor Registry

Diseases Treated:

Adrenocortical tumors (carcinoma and adenoma)

Eligibility:

  • Diagnosis of an adrenocortical tumor (ACT)
  • 21 years of age or younger at diagnosis
  • Relatives of patients with ACT
View Trial

LITE: Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed with Solid Tumors: A Pilot Study

Diseases Treated:

Solid tumors

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • At least 12 years old 
  • Diagnosed with a solid tumor or lymphoma within the past 30 days 
  • Speaks, reads and writes in English or Spanish
  • No blindness or history of eye disease including, but not limited to macular degeneration, or other diagnosed retinal problems 
  • Not initiated antidepressant medication, including either SSRIs in the past month, and MAOIs in the past two months
  • No laser corrective eye surgery in the past 30 days
View Trial

MARB: Molecular Analysis of Retinoblastoma

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

View Trial

RETCELL: A Study of Children with Heritable Retinoblastoma

Diseases Treated:

Retinoblastoma (non-therapeutic)

Eligibility:

Family history of retinoblastoma with one of the following:

  • RB1 mutation OR
  • Diagnosis of bilateral retinoblastoma OR
  • Diagnosis of unilateral retinoblastoma with RB1 mutation or MYCN amplification
View Trial

U-CHAT: Understanding Communication in Health Care to Achieve Trust

Diseases Treated:

Non-therapeutic

Eligibility:

Primary oncologist:

  • Attending physician age 18 years or older who provides medical care to patients in the Solid Tumor Clinic at St. Jude Children’s Research Hospital
  • Primary hematology-oncology fellows age 18 or older (audio-recorded disease reevaluation only)

Parents of children with cancer:

  • Age 18 or older
  • Biological parent, step-parent or primary legal guardian
  • Reads and speaks English

Patients:

  • Primary oncologist is enrolled in the study.
  • 30 years old or younger
  • Diagnosed with one or more of the  following diseases:
    • High-risk neuroblastoma
    • Any sarcoma
    • Any carcinoma
    • Desmoplastic small round cell tumor
    • Incompletely resected or metastatic retinoblastoma, Wilms tumor, germ cell tumor, hepatoblastoma or melanoma
    • Disease has relapsed, progressed or not responded to therapy
View Trial

Collaborative Clinical Studies

MACMEL: A Study to Analyze Melanoma Lesions in Children and Teens

Diseases Treated:

Melanoma

Eligibility:

  • Diagnosed with a melanoma tumor that is malignant (cancerous) or that might be cancerous, including:
    • Conventional or “adult-type” melanoma
    • Spitzoid melanoma/atypical Spitz tumor
    • Congenital melanoma
    • Melanoma arising in a giant congenital nevus
    • Melanocytic lesions with indeterminate biological behavior (e.g., pigment-synthesizing melanomas)
  • Younger than 19 years of age 
View Trial

PDMCRN: Parental Decision-Making for Children with Relapsed Neuroblastoma

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant is the parent of a child with relapsed or refractory high risk neuroblastoma receiving primary oncology care or a second opinion at a participating site.
  • Parent aged 18 year or older, of a child aged ≤ 18 years.
  • Participating parent if the primary decision maker for the family.
  • Participating parent is English-speaking.
View Trial